Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-05-19
DOI
10.1016/j.annonc.2023.05.005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era
- (2022) Benoit You et al. BRITISH JOURNAL OF CANCER
- Efficacy of maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer according to BRCA mutation genotype in the phase III PAOLA-1/ENGOT-ov25 trial.
- (2022) Sana Intidhar Labidi-Galy et al. JOURNAL OF CLINICAL ONCOLOGY
- A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)
- (2022) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
- (2022) Ignace Vergote et al. LANCET ONCOLOGY
- Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial
- (2022) Antonio González-Martín et al. EUROPEAN JOURNAL OF CANCER
- Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
- (2022) Paul DiSilvestro et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines
- (2021) N. Colombo et al. ANNALS OF ONCOLOGY
- Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer
- (2021) Ignace Vergote et al. EUROPEAN JOURNAL OF CANCER
- ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
- (2021) Bradley J Monk et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
- (2021) I. Vergote et al. ANNALS OF ONCOLOGY
- ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†
- (2019) N Colombo et al. ANNALS OF ONCOLOGY
- Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
- (2019) Krishnansu S. Tewari et al. JOURNAL OF CLINICAL ONCOLOGY
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2019) Antonio González-Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
- (2019) Robert L. Coleman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
- (2019) Isabelle Ray-Coquard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- European Network of Gynaecological Oncological Trial Groups’ Requirements for Trials Between Academic Groups and Industry Partners—First Update 2015
- (2015) Andreas du Bois et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Detecting Overall Survival Benefit Derived From Survival Postprogression Rather Than Progression-Free Survival
- (2015) Satoshi Morita et al. JNCI-Journal of the National Cancer Institute
- Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
- (2015) Amit M Oza et al. LANCET ONCOLOGY
- Detecting Overall Survival Benefit Derived From Survival Postprogression Rather Than Progression-Free Survival
- (2015) Satoshi Morita et al. JNCI-Journal of the National Cancer Institute
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Pharmaceutical Companies
- (2010) Ignace Vergote et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
- (2009) Kristine R. Broglio et al. JNCI-Journal of the National Cancer Institute
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now